Copenhagen index (CPH-I) is more favorable than CA125, HE4, and risk of ovarian malignancy algorithm (ROMA): Nomogram prediction models with clinical-ultrasonographic feature for diagnosing ovarian neoplasms

被引:5
作者
Song, Zixuan [1 ]
Wang, Xiaoxue [2 ]
Fu, Jiajun [3 ]
Wang, Pengyuan [4 ]
Chen, Xueting [2 ]
Zhang, Dandan [1 ]
机构
[1] China Med Univ, Dept Obstet & Gynecol, Shengjing Hosp, Shenyang, Peoples R China
[2] China Med Univ, Dept Hlth Management, Shengjing Hosp, Shenyang, Peoples R China
[3] China Med Univ, Dept Pathol, Shengjing Hosp, Shenyang, Peoples R China
[4] China Med Univ, Dept Radiol, Shengjing Hosp, Shenyang, Peoples R China
关键词
ovarian neoplasms; epithelial ovarian cancer; CA125; HE4; risk of ovarian malignancy algorithm (ROMA); Copenhagen index (CPH-I); nomogram; prediction model; MENOPAUSAL STATUS; PREOPERATIVE DIAGNOSIS; CANCER; ULTRASOUND; TUMORS; WOMEN; MULTICENTER; PERFORMANCE; EXPRESSION; BIOMARKERS;
D O I
10.3389/fsurg.2022.1068492
中图分类号
R61 [外科手术学];
学科分类号
摘要
BackgroundWe aimed to analyze the benign and malignant identification efficiency of CA125, HE4, risk of ovarian malignancy algorithm (ROMA), Copenhagen Index (CPH-I) in ovarian neoplasms and establish a nomogram to improve the preoperative evaluation value of ovarian neoplasms. MethodsA total of 3,042 patients with ovarian neoplasms were retrospectively classified according to postoperative pathological diagnosis [benign, n = 2389; epithelial ovarian cancer (EOC), n = 653]. The patients were randomly divided into training and test cohorts at a ratio of 7:3. Using CA125, HE4, ROMA, and CPH-I, Receiver operating characteristic (ROC) curves corresponding to different truncation values were calculated and compared, and optimal truncation values were selected. Clinical and imaging risk factors were calculated using univariate regression, and significant variables were selected for multivariate regression analysis combined with ROMA and CPH-I. Nomograms were constructed to predict the occurrence of EOC, and the accuracy was assessed by external validation. ResultsWhen the cutoff value of CA125, HE4, ROMA, and CPH-I was 100 U/ml, 70 pmol/L, 12.5/14.4% (premenopausal/postmenopausal) and 5%, respectively, the AUC was 0.674, 0.721, 0.750 and 0.769, respectively. From univariate regression, the clinical risk factors were older age, menopausal status, higher birth rate, hypertension, and diabetes; imaging risk factors were multilocular tumors, solid nodules, bilateral tumors, larger tumor diameter, and ascites. The AUC of the nomogram containing ROMA and CPH-I was 0.8914 and 0.9114, respectively, which was better than the prediction accuracies of CA125, HE4, ROMA, and CPH-I alone. The nomogram with CPH-I was significantly better than that with ROMA (P < 0.001), and a nomogram decision curve analysis (DCA) containing CPH-I seemed to have better clinical benefits than ROMA. For external validation of this nomogram containing ROMA and CPH-I, the C-indices were 0.889 and 0.900, and the calibration curves were close to 45 degrees, showing good agreement with the predicted values. ConclusionWe conclude that CPH-I and ROMA have higher diagnostic values in the preoperative diagnosis of EOC than other single tumor markers like CA125 or HE4. A nomogram based on CPH-I and ROMA with clinical and ultrasonic indicators had a better diagnostic value, and the CPH-I nomogram had the highest diagnostic efficacy.
引用
收藏
页数:13
相关论文
共 51 条
[1]   New Analytical Approach for the Alignment of Different HE4 Automated Immunometric Systems: An Italian Multicentric Study [J].
Angeloni, Antonio ;
De Vito, Corrado ;
Farina, Antonella ;
Terracciano, Daniela ;
Cennamo, Michele ;
Passerini, Rita ;
Bottari, Fabio ;
Schirinzi, Annalisa ;
Vettori, Roberto ;
Steffan, Agostino ;
Mais, Valerio ;
Coghe, Ferdinando ;
Della Corte, Luigi ;
Bifulco, Giuseppe ;
Baccolini, Valentina ;
Berardelli, Elena ;
Migliara, Giuseppe ;
Anastasi, Emanuela .
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (07)
[2]   Ovarian Cancer Biomarkers: Moving Forward in Early Detection [J].
Bonifacio, Vasco D. B. .
TUMOR MICROENVIRONMENT: THE MAIN DRIVER OF METABOLIC ADAPTATION, 2020, 1219 :355-363
[3]   The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects [J].
Bottoni, Patrizia ;
Scatena, Roberto .
ADVANCES IN CANCER BIOMARKERS: FROM BIOCHEMISTRY TO CLINIC FOR A CRITICAL REVISION, 2015, 867 :229-244
[4]   CA125 and Ovarian Cancer: A Comprehensive Review [J].
Charkhchi, Parsa ;
Cybulski, Cezary ;
Gronwald, Jacek ;
Wong, Fabian Oliver ;
Narod, Steven A. ;
Akbari, Mohammad R. .
CANCERS, 2020, 12 (12) :1-29
[5]   Age and menopausal status are important factors influencing the serum human epididymis secretory protein 4 level: a prospective cross-sectional study in healthy Chinese people [J].
Cheng, Hong-Yan ;
Zeng, Lin ;
Ye, Xue ;
Ma, Rui-Qiong ;
Tang, Zhi-Jian ;
Chu, Hong-Ling ;
Zhao, Yi-Ming ;
Zhu, Li-Rong ;
Gao, Yu-Nong ;
Chang, Xiao-Hong ;
Cui, Heng .
CHINESE MEDICAL JOURNAL, 2020, 133 (11) :1285-1291
[6]   Clinical value of ROMA index in diagnosis of ovarian cancer: meta-analysis [J].
Cui, Ranliang ;
Wang, Yichao ;
Li, Ying ;
Li, Yueguo .
CANCER MANAGEMENT AND RESEARCH, 2019, 11 :2545-2551
[7]   Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer A Meta-analysis [J].
Dayyani, Farshid ;
Uhlig, Steffen ;
Colson, Bertrand ;
Simon, Kirsten ;
Rolny, Vinzent ;
Morgenstern, David ;
Schlumbrecht, Matthew .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (09) :1586-1593
[8]   Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review [J].
Dochez, Vincent ;
Caillon, Helene ;
Vaucel, Edouard ;
Dimet, Jerome ;
Winer, Norbert ;
Ducarme, Guillaume .
JOURNAL OF OVARIAN RESEARCH, 2019, 12 (1)
[9]   Personalizing CA125 Levels for Ovarian Cancer Screening [J].
Dorigo, Oliver ;
Berek, Jonathan S. .
CANCER PREVENTION RESEARCH, 2011, 4 (09) :1356-1359
[10]   Early Detection of Ovarian Cancer [J].
Elias, Kevin M. ;
Guo, Jing ;
Bast, Robert C., Jr. .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2018, 32 (06) :903-+